About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
2024
Submit
November 20, 2024
Verrica Announces Proposed Public Offering
November 4, 2024
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
October 31, 2024
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
October 2, 2024
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
September 4, 2024
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
1
2
3
4
5
6
next >
